Can Pfizer Achieve High-Single-Digit Revenue CAGR From 2029?
Can Pfizer Achieve High-Single-Digit Revenue CAGR From 2029?
Pfizer is aiming for a stronger growth phase after 2028, as the company works to move beyond falling COVID-19 product sales and upcoming patent expirations. The drugmaker has said it sees a path toward a high-single-digit revenue CAGR over a five-year period beginning in 2029, supported by oncology, obesity treatments, vaccines, and newly acquired medicines.
Pfizer’s Long-Term Growth Target
The key question for investors is whether Pfizer can turn its pipeline and recent acquisitions into steady revenue growth. The company’s management believes it can return to more reliable expansion after 2028, when some major patent-related pressures are expected to ease.
In the first quarter of 2026, Pfizer reported revenue of about $14.5 billion, up 5% year over year. Excluding COVID-19 products, revenue grew 7% operationally, showing that its core business is improving even as pandemic-related sales continue to decline. Pfizer also reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion.
Why 2029 Matters
Pfizer faces a major transition before 2029. Several key drugs, including products such as Eliquis and Ibrance, face loss-of-exclusivity risks. These patent cliffs could reduce annual revenue by billions of dollars if replacement products do not grow quickly enough.
However, Pfizer is trying to offset that pressure through new launches, acquired assets, and deeper investment in high-growth areas. Management has pointed to oncology, obesity medicines, vaccines, inflammation, immunology, and rare disease treatments as possible engines for future expansion.
Oncology Remains a Central Growth Driver
One of Pfizer’s strongest opportunities is cancer treatment. The company’s acquisition of Seagen gave it a larger oncology portfolio, including important drugs such as Padcev. In the first quarter of 2026, products like Padcev helped support Pfizer’s sales growth, while launched and acquired products grew 22% operationally.
This is important because oncology is one of the largest and fastest-moving areas in global healthcare. If Pfizer can expand approvals, grow international sales, and combine new cancer therapies with its existing commercial network, oncology could become a major source of post-2028 growth.
Obesity Drugs Could Open a Major New Market
Pfizer is also investing in the obesity treatment market, which has become one of the most competitive areas in pharmaceuticals. The company’s acquisition of Metsera gives it another chance to build a presence in weight-loss medicines after earlier setbacks in its internal obesity programs.
Reuters reported that Pfizer expects its first product from the Metsera acquisition around 2028, positioning the company to participate in a market that could become worth more than $100 billion annually.
COVID-19 Declines Still Create Pressure
Pfizer’s biggest challenge remains the sharp fall in COVID-19 vaccine and antiviral demand. Comirnaty and Paxlovid were once massive revenue contributors, but sales have dropped as global pandemic demand normalized.
Still, Pfizer’s latest results suggest the company is becoming less dependent on COVID-19 products. Its non-COVID portfolio is growing, and management is focusing more on durable medicines that can support long-term revenue.
Cost Controls and R&D Spending
Pfizer is also trying to improve profitability through cost savings and operational efficiency. At the same time, it is increasing research and development spending in areas such as oncology and obesity. This balance is important because cutting costs can support earnings now, while R&D investment is needed to create future growth.
In Q1 2026, Pfizer’s adjusted diluted earnings per share were $0.75, while reported diluted EPS was $0.47. The company kept its full-year adjusted EPS guidance at $2.80 to $3.00.
Can Pfizer Really Reach High-Single-Digit CAGR?
Pfizer can reach high-single-digit revenue CAGR from 2029, but it will not be easy. The company needs several things to go right at the same time. Its oncology portfolio must continue expanding, obesity candidates must succeed in trials and launches, and newer acquired products must grow fast enough to replace revenue lost from older drugs.
The target is realistic if Pfizer delivers strong clinical results, wins new approvals, and executes well commercially. However, investors should also consider risks, including trial failures, pricing pressure, competition from Eli Lilly and Novo Nordisk in obesity, and continued patent-related revenue losses.
Conclusion
Pfizer is entering a difficult but important transition period. The company is no longer enjoying the extraordinary COVID-19 sales boom, and patent expirations will remain a major concern through 2028. Even so, Pfizer has meaningful growth opportunities in oncology, obesity, vaccines, and acquired medicines.
If management executes well, Pfizer may be able to achieve high-single-digit revenue CAGR beginning in 2029. The path is promising, but success will depend on pipeline performance, product launches, and the company’s ability to turn recent acquisitions into long-term revenue growth.
#Pfizer #PFEStock #PharmaNews #HealthcareInvesting #SlimScan #GrowthStocks #CANSLIM